Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis

Artificial Organs

Volumn 22, Issue 8, 1998, Pages 633-637

  Egfjord, Martin ^a,b   Rosenlund, Lene ^a   Hedegaard, Berit ^a   Buchardt, Helle Løvdahl ^a   Stengel, Christina ^a   Gardar, Petra ^a   Andersen, Lisbeth ^a   Andersen, Louise ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Chronic renal failure; Hemodialysis; Low molecular weight heparin

Indexed keywords

BLOOD; HEMODIALYZERS; HEMODYNAMICS; MOLECULAR WEIGHT; PATIENT TREATMENT; POLYSACCHARIDES; SWITCHING;

BLEEDING TIME; BLEEDINGS; BLOOD-FLOW RATES; CHRONIC RENAL FAILURE; DENMARK; HAEMODIALYSIS; HOLLOW FIBER; LOW-MOLECULAR WEIGHT HEPARINS; TOTAL DOSE; VISUAL INSPECTION;

DIALYSIS;

LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DRUG DETERMINATION; FEMALE; HEMODIALYSIS; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL;

PANTHERA;

EID: 0031871361     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06008.x     Document Type: Article

References (13)

1. Larsson SO. On coagulation and fibrinolysis in uraemic patients on maintenance haemodialysis. Acta Med Scand 1971; 189:453-62.
2. Turney JH, Woods HF, Freewell MR, Weston MJ. Factor VIII complex in uremia and effects on hemodialysis. Br Med J 1981;282:1653-6.
3. Wessel-Aas T, Blomhoff JP, Wirum E, Nilson T. Hemodialysis and cell toxicity in vitro related to plasma triglycerides, post-heparin lipotytic activity and free fatty acids. Acta Med Scand 1984;216:75-83.
4. Crawford GA, Savdie E, Stewart JH. Heparin-released plasma lipases in chronic renal failure and after renal transplantation. Clin Sci 1979;57:155-65.
5. Nurmohamed MT, Cate JT, Stevens P, Hoeck JA, Lins RL, Cate J-W. Long-term efficacy and safety of low molecular weight heparin in chronic hemodialysis patients. ASAIO Trans 1991;37:M459-61.
6. Grau E, Sigüenza F, Maduell F, Linares M, Olaso MA, Martinez R, Caridad A. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992;62:13-7.
7. Schrader J, Stibbe W, Armstrong VA, Kandt M, Muche R, Köstering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/ hemofiltration. Kidney Int 1988;33:890-6.
8. Deuber HJ, Schultz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991;40:496-500.
9. Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): Influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993;8:438-42.
10. Ryan KE, Lane DA, Flynn A, Spepperd J, Ireland HA, Curtis JR. Dose finding study of low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991;66:277-82.
11. Hull RD et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New Engl J Med 1992;326: 975-82.
12. Simpson HKL, Baird J, Allison M, Briggs JD, Rowe PA, Welsh M, Macdougall AI, Grant AC, Lowe GDO, Rumley A, Wallace M, Menday AP. Long-term use of low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996;26:90-7.
13. Akiba T, Tachibana K, Ozawa K. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on haemodialysis. ASAIO J 1992;38:M326-30.